#elvitegravir

[ptmasterguide]

Elvitegravir

In this article, we will discuss about Elvitegravir (Overview). So, let’s get started. Elvitegravir is an HIV-1 integrase strand transfer inhibitor. The chemical name of elvitegravir is 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. It has a molecular formula of C23H23CIFNO5, and a molecular weight of 447.88.…

View On WordPress

[siglerprescriptiondrugcards]

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

Brand Name: Genvoya

Common Dosage Forms:

Tablets: Each tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide.

FDA Indications/Dosages:

Indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg, who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of this drug: One tablet daily taken with food.

Monitor: CrCL, urine glucose and protein, BMD, LFT

Pharmacology/Pharmacokinetics: Genvoya is a fixed dose combination of antiviral drugs elvitegravir, emtricitabine, and tenofovir alafenamide along with CYP3A inhibitor cobicistat. Elvitegravir inhibits the strand transfer activity of HIV-1 DNA integrase which prevents the integration of HIV-1 DNA into host genomic DNA. This inhibition blocks the formation of the HIV-1 provirus and propagation of the viral infection. Emtricitabine undergoes phosphorylation by cellular enzymes to form emtricitabine 5′-triphosphate, The metabolite inhibits the activity of HIV-1 RT by completing with the natural substrate deoxycytidine 5′-triphosphate. Incorporation of emtricitabine 5′-triphosphate into the viral DNA results in chain termination. Tenofovir alafenamide is phosphoramidate prodrug of tenofovir. Tenofovir is metabolized to the active tenofovir diphosphate where it inhibits the activity of HIV-1 RT by competing with deoxyadenosine 5′-triphosphate for incorporation into DNA. It ultimately causes chain termination. Cobicistat is a selective inhibitor of CYP3A which prolongs the half-life of elvitegravir. Peak plasma levels in the fasted state are different for each ingredient and range from 1-4 hours. Tenofovir and emtricitabine are primarily excreted as unchanged drug in the urine. Elvitegravir and cobicistat are metabolized primarily via the CYP3A isoenzyme.

Drug Interactions: Antacids, CARBAMAZEPINE, RIFAMPIN, PHENOBARBITAL, and dexamethasone may decrease elvitegravir may decrease elvitegravir concentration. May increase concentrations concentrations of antiarrhythmics, PIMOZIDE, ALFUZOSIN, digoxin, clarithromycin, clonazepam, ethosuximide, antidepressants, colchicine, antifungals, quetiapine, beta-blockers, calcium channel blockers, fluticasone, bosentan, atorvastatin, norgestimate, buprenorphine, immunosuppressants, salmeterol, PDE-inhibitors, and TRIAZOLAM. May decrease concentrations of ethinyl estradiol and naloxone. Drugs that reduce kidney function or compete with tubular secretion may increase concentrations of emtricitabine and tenofovir. ST. JOHN’S WORT may decrease concentrations. Do not use with LOVASTATIN, SIMVASTATIN, or any ergot derivatives due to potential for severe adverse effects.

Contraindications/Precautions: Coadministration is contraindicated with drugs that are highly dependent on CYP3A. Contraindicated with any of the drugs in the Drug Interactions section printed in all UPPER CASE letters. Severe acute exacerbations of hepatitis B may occur therefore patients should be tested for hepatitis before initiating treatment. Not recommended in patients with CrCL below 30 mL/min. Monitor renal function throughout therapy. Avoid use with other antiviral medications. May decrease bone mineral density therefore monitoring is suggested. Cases of lactic acidosis and severe hepatomegaly have occurred in patients taking tenofovir with other antiretrovirals. Pregnancy Category B.

Adverse Effects: The most common adverse effects are diarrhea, nausea, rash, fatigue, headache, dizziness, insomnia, and abnormal dreams. Rare but potentially severe adverse effects include lactic acidosis, severe hepatomegaly, Hepatitis B exacerbation, renal impairment, and decreased bone mineral density.

Patient Consultation:

Take with a meal.

If you miss a dose, take it as soon as you remember. If it is closer to the time of your next dose, skip the missed dose and carry on with your normal dosing schedule. Do not double doses.

Call your healthcare provider if you experience any symptoms of lactic acidosis (very weak, unusual muscle pain, breathing trouble, stomach pain with nausea or vomiting, fast or irregular heartbeat, dizziness, coldness in extremities).

Call your healthcare provider is you experience any symptoms of liver dysfunction (yellow skin or eyes, dark urine, light-colored stools, anorexia, stomach pain, or nausea).

This medication does not prevent you from transmitting HIV-1 to other people.

[fundacionluchandovenceras]

VITEKTA ELVITEGRAVIR EVG Inhibidor de la integrasa . . . . . #vitekta #elvitegravir #arv #retrovirrales #antiretrovirrales #medicos #medicines #medic #medicine #saludemocional #saludresponsable #saludybienestar #salud #saludmentalyemocional #saludables #concienciaplena #concienciasocial #concienciauniversal #conciencia https://www.instagram.com/p/CB3oqFljb_c/?igshid=mn1prpul6h7m

[fundacionluchandovenceras]

GENVOYA ELVITEGRAVIR/ COBICISTAT/EMTRICITABINA /ALAFENAMIDA EVG/COBI/FTC/TAF, elvitegravir / cobicistat /emtricitabina / fumarato de Alafenamida de Tenofovir #genvoya #elvitegravir #cobicistat #entricitabina #alafenamida #tenofovir #arv #retrovirrales #antiretrovirrales #salud #conciencia #diversidad #medicine #medicinas #medic #medicamentos #remedios https://www.instagram.com/p/CAqhb5hH8EC/?igshid=hyrmifrq6or8

[amcrasto]

FDA approves new treatment for HIV

FDA approves new treatment for HIV

  FDA approves new treatment for HIV 11/05/2015 12:53 PM EST The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older…

View On WordPress

[hivforum]

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

The debut of TAF. We can now stop calling it “E/C/F/TAF” or “Stribild 2.0″ or “Stribild with TAF in it.”

[soropositivoorg]

Elvitegravir otimizado por atazanavir traz resultados melhores para mulheres, demonstra estudo!

O estudo WAVES mostra que o esquema elvitegravir otimizado por atazanavir traz resultados melhores para mulheres com HIV

Nota do Tradutor o nome do estou é WAVES, um acrônimo para Women AntiretroViral Efficacy and Safety que significa, em tradução livre: As mulheres,a eficácia e segurança da terapia antiretroviral. Uma vez estabelecido isso, boa leitura

Um estudo do tratamento antirretroviral…

View On WordPress

[amcrasto]

FDA Approves Vitekta (elvitegravir) for HIV-1 Infection

FDA Approves Vitekta (elvitegravir) for HIV-1 Infection

  FDA Approves Vitekta (elvitegravir) for HIV-1 Infection

September 24, 2014 — The U.S. Food and Drug Administration (FDA) has approved Vitekta (elvitegravir), an integrase strand transfer inhibitor for the combination treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment-experienced adults.

    Elvitegravir

697761-98-1 CAS

  Elvitegravir (EVG, formerly GS-9137) is a…

View On WordPress